Axsome Therapeutics Inc (NASDAQ: AXSM) has reported E.P.S. of $-1.54 for its fourth fiscal quarter (ending December 31) versus $-2.08 for the same period a year ago — a decline of -26%. For the latest four quarters through December 31, E.P.S. were $-5.99 compared to $-5.27 a year ago — an increase of 14%.
Recent Price Action
On 2/18/25, Axsome Therapeutics Inc (NASDAQ: AXSM) stock declined by -2.3%, closing at $128.09. Moreover, this decline was accompanied by unusually high trading volume at 153% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 21.1% during the last week.
Current PriceTarget Research Rating
Axsome Therapeutics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Axsome Therapeutics has a very low Appreciation Score of 4 but a slightly positive Power Rating of 66, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment